- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
452
Companies which are more than 50% undervalued based on analyst price target.
452 companies
CASI Pharmaceuticals
Market Cap: US$26.2m
A biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally.
CASI
US$1.75
7D
15.8%
1Y
-67.9%
Neuphoria Therapeutics
Market Cap: US$26.0m
A clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia.
NEUP
US$14.64
7D
17.6%
1Y
n/a
Passage Bio
Market Cap: US$25.8m
A genetic medicines company, develops gene therapies for central nervous system diseases.
PASG
US$8.05
7D
4.8%
1Y
-32.9%
Q32 Bio
Market Cap: US$25.4m
A clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction.
QTTB
US$2.07
7D
10.1%
1Y
-95.2%
MIRA Pharmaceuticals
Market Cap: US$25.2m
Operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
MIRA
US$1.34
7D
3.1%
1Y
14.5%
MetaVia
Market Cap: US$24.9m
A clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases.
MTVA
US$0.98
7D
-1.8%
1Y
-62.9%
Enlivex Therapeutics
Market Cap: US$24.6m
Operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.
ENLV
US$1.04
7D
1.0%
1Y
-34.2%
ProMIS Neurosciences
Market Cap: US$24.5m
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
PMN
US$0.47
7D
17.3%
1Y
-57.8%
Cingulate
Market Cap: US$23.5m
A biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.
CING
US$4.06
7D
7.1%
1Y
-15.8%
Kairos Pharma
Market Cap: US$23.4m
A clinical-stage biopharmaceutical company, develops therapeutics for cancer patients.
KAPA
US$1.15
7D
0.9%
1Y
-15.4%
IO Biotech
Market Cap: US$23.4m
A clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform.
IOBT
US$0.43
7D
-72.5%
1Y
-56.9%
Citius Pharmaceuticals
Market Cap: US$23.3m
A biopharmaceutical company, focuses on the development and commercialization of critical care products.
CTXR
US$1.33
7D
15.7%
1Y
-88.1%
FibroBiologics
Market Cap: US$21.9m
Operates as a cell therapy, regenerative medicine company.
FBLG
US$0.54
7D
0.06%
1Y
-79.6%
Clearside Biomedical
Market Cap: US$21.9m
A biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
CLSD
US$4.07
7D
9.1%
1Y
-79.6%
Rallybio
Market Cap: US$21.7m
A clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
RLYB
US$0.51
7D
-9.5%
1Y
-53.5%
Lisata Therapeutics
Market Cap: US$21.5m
A clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.
LSTA
US$2.55
7D
7.8%
1Y
-13.3%
SenesTech
Market Cap: US$21.3m
Engages in the development and commercialization of a technology for managing animal pest populations through fertility control.
SNES
US$3.94
7D
-10.5%
1Y
62.1%
Hoth Therapeutics
Market Cap: US$21.2m
A clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs.
HOTH
US$1.56
7D
-13.8%
1Y
99.6%
Curis
Market Cap: US$20.9m
A biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
CRIS
US$1.61
7D
-1.8%
1Y
-67.9%
Allarity Therapeutics
Market Cap: US$20.7m
A clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs.
ALLR
US$1.62
7D
5.2%
1Y
-5.3%
SAB Biotherapeutics
Market Cap: US$20.6m
A clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders.
SABS
US$2.01
7D
-4.3%
1Y
-18.3%
Harvard Bioscience
Market Cap: US$19.9m
Develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally.
HBIO
US$0.46
7D
4.6%
1Y
-81.3%
Lexaria Bioscience
Market Cap: US$19.1m
Operates as a biotechnology company.
LEXX
US$0.89
7D
-41.9%
1Y
-73.1%
Aytu BioPharma
Market Cap: US$18.5m
A pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.
AYTU
US$1.97
7D
5.9%
1Y
-17.9%
Cellectar Biosciences
Market Cap: US$18.4m
A clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.
CLRB
US$5.80
7D
0.9%
1Y
-91.0%
Edesa Biotech
Market Cap: US$18.1m
A clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.
EDSA
US$2.75
7D
12.7%
1Y
-35.6%
Abpro Holdings
Market Cap: US$18.0m
A biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology.
ABP
US$0.23
7D
7.1%
1Y
-98.0%
Bionano Genomics
Market Cap: US$16.8m
Provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
BNGO
US$1.89
7D
10.5%
1Y
-92.8%
Cocrystal Pharma
Market Cap: US$16.4m
A biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States.
COCP
US$1.22
7D
-2.4%
1Y
-29.5%
iBio
Market Cap: US$16.2m
A preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
IBIO
US$0.83
7D
4.7%
1Y
-63.1%
Lipocine
Market Cap: US$16.1m
A clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders.
LPCN
US$3.09
7D
15.3%
1Y
-31.0%
Longeveron
Market Cap: US$15.6m
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
LGVN
US$0.77
7D
-3.6%
1Y
-57.3%
Palisade Bio
Market Cap: US$15.5m
A clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.
PALI
US$1.70
7D
119.9%
1Y
-52.2%
Pharma-Bio Serv
Market Cap: US$15.4m
Operates as a regulatory affairs, compliance, and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally.
PBSV
US$0.62
7D
3.3%
1Y
-4.6%
NextCure
Market Cap: US$15.2m
A clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer.
NXTC
US$5.75
7D
-0.5%
1Y
-63.4%
BioVie
Market Cap: US$15.0m
A clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.
BIVI
US$2.00
7D
11.1%
1Y
-83.1%